Rocket Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript
Welcome, everyone, to the JPMorgan Healthcare Conference. My name is Tessa Romero, and I'm one of the Senior Biotech Analysts here at JPMorgan. Our next presenting company is Rocket Pharmaceuticals. And presenting on behalf of the company, we have CEO, Gaurav Shah.
Gaurav, over to you.
Thank you for having us. Welcome to 2026. Thanks, Tessa, for hosting us and JPMorgan as well. Standard disclaimer, forward-looking statement disclaimer here. So Rocket is a late-stage biotech company. We have a pipeline of gene therapies that are designed to correct the root cause of complex and rare genetic diseases.
We have two platforms, AAV and lentiviral and we do everything from discovery to manufacturing, including in-house manufacturing for AAV. And we think that the secret sauce to success in gene therapy is an asset selection. And we're focused on assets that target medical conditions that are not only rare, but are devastating
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
